NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies"

BETHESDA, Md., April 16, 2015 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that it has been included in the Loncar Cancer Immunotherapy Index (LCINDX), a professional index recently established to help investors better track the immunotherapy field within the biotechnology space. 

The Index founders have selected "the top 25 companies" in the immunotherapy space, including 6 big pharma companies and 19 growth-oriented biotech companies.  The Index is designed to capture the contributions of leading companies, both large and small, to the progress of the immunotherapy field.  The Index currently ranks NW Bio 8^th among the 25 companies included. 

The Index can be tracked on a daily basis at http://www.loncarindex.com/ 

The Index is based upon the founders' view that "immunotherapy is a transformational field within the biotechnology space" and that "areas like immunotherapy trade on their own unique circumstances and innovations." 

"We welcome the advent of this new Index for the rapidly advancing immunotherapy space," commented Linda Powers, CEO of NW Bio.  "We appreciate the Loncar Index' approach in assessing the companies included, and we are pleased to see a recognition of NW Bio's progress and position as a leader in the immunotherapy space." 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).  GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression.  It has completed enrollment in the Phase I portion of the trial.  The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer.  The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.  In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS:

Les Goldman  
202-841-7909   
[email protected]                                                 

Farrell Kramer (Media) 
212-710-9685 
[email protected]

Jane Searle (Investors) 
212-710-9686 
[email protected]

www.nwbio.com

SOURCE Northwest Biotherapeutics, Inc.

Related Links

http://www.nwbio.com